Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same

• US 20080220069A1
• Filed: 09/13/2005
• Published: 09/11/2008
• Est. Priority Date: 09/13/2004
• Status: Abandoned Application

• Current Assignee: PR Pharmaceuticals Incorporated
• Original Assignee: PR Pharmaceuticals Incorporated
• Inventors: Allison, S. Dean
• Application Number:
  US11/663,003
• Publication Number:
  US 20080220069A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of diseases.

Claims

1. A composition of comprising;

an estradiol metabolite whereby the in vivo pharmacokinetics of said estradiol metabolite are manipulated by a procedure comprising one or more of chemical modification, crystal packing formation and particle size.

2. The composition of claim 1, wherein said estradiol metabolite further comprises a suspending agent.

4. The composition of claim 1, wherein said estradiol metabolite comprises one or more of 2-methoxyestradiol, 2-hydroxyestradiol, 4-methoxyestradiol, and 4-hydroxyestradiol.

5. The composition of claim 1, wherein said estradiol metabolite is a prodrug.

6. The composition of claim 5, wherein said prodrug is an ester.

7. The composition of claim 6, wherein said ester comprises one or more of 3-benzoyl-2-methoxyestradiol;

17-benzoyl-2-methoxyestradiol;

17-acetyl-2-methoxyestradiol;

3-acetyl-2-methoxyestradiol;

3,17-benzoyl-2-methoxyestradiol;

3,17-diacetyl-2-methoxyestradiol;

3-benzoyl-4-methoxyestradiol;

17-benzoyl-4-methoxyestradiol;

17-acetyl-4-methoxyestradiol;

3-acetyl-4-methoxyestradiol;

3,17-dibenzoyl-4-methoxyestradiol;

3,17-diacetyl-4-methoxyestradiol;

3-benzoyl-2-hydroxyestradiol;

17-benzoyl-2-hydroxyestradiol;

17-acetyl-2-hydroxyestradiol;

3-acetyl-2-hydroxyestradiol;

3,17-dibenzoyl-2-hydroxyestradiol;

3,17-diacetyl-2-hydroxyestradiol;

2,3-dibenzoyl-2-hydroxyestradiol;

2,17-dibenzoyl-2-hydroxyestradiol;

2,17-diacetyl-2-hydroxyestradiol;

2,3-diacetyl-2-hydroxyestradiol;

2,3,17-tribenzoyl-2-hydroxyestradiol;

2,3,17-triacetyl-2-hydroxyestradiol;

3-benzoyl-4-hydroxyestradiol;

17-benzoyl-4-hydroxyestradiol;

17-acetyl-4-hydroxyestradiol;

3-acetyl-4-hydroxyestradiol;

3,17-dibenzoyl-4-hydroxyestradiol;

3,17-diacetyl-4-hydroxyestradiol;

3,4-dibenzoyl-4-hydroxyestradiol;

4,17-dibenzoyl-4-hydroxyestradiol;

4,17-diacetyl-4-hydroxyestradiol;

3,4-diacetyl-4-hydroxyestradiol;

3,4,17-tribenzoyl-4-hydroxyestradiol; and

3,4,17-triacetyl-4-hydroxyestradiol.

8. The composition of claim 1, wherein said chemical modification includes derivatization of said estradiol metabolite.

9. The composition of claim 8, wherein said derivative comprises one or more of dicarboxylic acid compounds, diacids, polar compounds, and ionic compounds.

10. The composition of claim 9, wherein such dicarboxylic acid compound comprises one or more of oxalic, malonic, maleic, succinic, glutaric, adipic, pimelic, and pamoic acid.

11. The composition of claim 1, wherein said estradiol metabolite comprises an analog.

12. The composition of claim 11, wherein said estradiol metabolite comprises a prodrug.

13. The composition of claim 1, wherein the estradiol metabolite, estradiol metabolite prodrug, or estradiol metabolite analog has sufficient solubility to achieve the desired steady state tissue concentration within an individual after administration.

14. The composition of claim 1, wherein said estradiol metabolite is in crystalline form.

15. The composition of claim 14, wherein the crystal structure is appropriate to allow sustained in-vivo dissolution of said estradiol metabolite after administration to an individual.

16. The composition of claim 15, wherein the particle size is appropriate to allow sustained in-vivo dissolution of the estradiol metabolite after administration to an individual.

17. The composition of claim 16, wherein the estradiol metabolite has been manipulated by chemical modification, crystal structure, or particle size, or any combination thereof to achieve an appropriate dissolution rate and steady state concentration after administration to an individual.

18. The composition of claim 1, wherein the suspending agent contains a surface active agent.

19. The composition of claim 18, wherein the suspending agent may be chosen from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone tyloxapol, a poloxamer, a polyoxamine dextran lecithin a dialkylester of sodium sulfosuccinic acid, sodium lauryl sulfate, an alkyl aryl polyether sulfonate, a polyoxyethylene sorbitan fatty acid ester, polyethylene glycol, a mixture of sucrose stearate and sucrose distearate, C₁₈H₃₇CH₂(CON(CH₃)CH₂(CHOH)₄(CH₂OH)₂, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxy propylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, and isononylphenoxypoly(glycidol).

20. The composition of claim 15, wherein the duration of action may be selected to range from a period of three days to a period of one year.

21. The composition of claim 20, wherein the drug, in combination with the suspending agent, is injected into an individual by subcutaneous, subgingival, intramuscular, intraperitoneal, or intraocular routes.

22. The composition of claim 1, wherein said estradiol metabolite comprises 2-methoxyestradiol in a concentration ranging from 20 to 200 mg/ml.

30. The composition of claim 1, wherein said manipulation by crystal packing structure comprises one or more of annealing, grinding, or milling to achieve a defined particle size distribution.

31. The composition of claim 30, wherein said composition comprises particles having more than one size distribution.

32. The composition of claim 1, wherein said chemical modification is reversible upon dissolution in a physiological environment.

33. The composition of claim 1, wherein said composition provides a reduction in the symptoms of metabolic disease and endothelin-1 levels.

34. The composition of claim 14, wherein said crystalline form is formed by one or more of thermal treatment, spray drying or antisolvent precipitation.

35. The composition of claim 1, wherein said composition is injectable.

36. The composition of claim 2, wherein the diluent is polyethylene glycol and the estradiol metabolite is soluble.

39. A sustained release formulation containing the composition of claim 1.

3. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

37. An injectable sustained release composition comprising an estradiol metabolite, wherein the in vivo pharmacokinetics of said composition are manipulated by a procedure comprising one or more of chemical modification, crystal packing formation and particle size.

38. A sustained release composition comprising a crystalline estradiol metabolite.